HODGKIN LYMPHOMA DIAGNOSED DURING THE SECOND TRIMESTER OF PREGNANCY AND TREATED WITH ABVD CHEMOTHERAPY WITH FAVORABLE MATERNAL AND NEONATAL OUTCOMES: A CASE REPORT.
This case report describes a pregnant 25-year-old with classical Hodgkin lymphoma who received two antenatal ABVD cycles, delivered a healthy neonate at 37 weeks, and achieved complete remission after completing chemotherapy postpartum.
Open original publication →What the AI sees
This case report describes a pregnant 25-year-old with classical Hodgkin lymphoma who received two antenatal ABVD cycles, delivered a healthy neonate at 37 weeks, and achieved complete remission after completing chemotherapy postpartum.
Research significance
The reported case provides evidence that ABVD administration during later pregnancy can coincide with favorable short-term maternal and neonatal outcomes under multidisciplinary monitoring; it only supports the inference—not proof—that this approach may be feasible for selected pregnant patients with Hodgkin lymphoma.
Source abstract
BACKGROUND: Hodgkin lymphoma (HL) during pregnancy is rare and presents diagnostic and therapeutic challenges. Optimal management requires balancing maternal oncologic benefit and fetal safety through a multidisciplinary approach. CASE PRESENTATION: A 25-year-old Armenian woman presented at 26 weeks' gestation with fatigue, night sweats, and significant weight loss. Magnetic resonance imaging without contrast revealed an anterior mediastinal mass. Histopathology confirmed classical Hodgkin lymphoma, nodular sclerosis subtype. Following multidisciplinary discussion, antenatal chemotherapy with the ABVD regimen was initiated. Two cycles were administered during pregnancy with close maternal and fetal monitoring. Pregnancy progressed uneventfully to 37 weeks, when a planned cesarean section was performed. A healthy male neonate was delivered with good Apgar scores. Postpartum, the mother completed chemotherapy and achieved complete remission. CONCLUSIONS: This case demonstrates that Hodgkin lymphoma diagnosed during the second trimester can be safely treated with ABVD chemotherapy during pregnancy when managed by a multidisciplinary team, resulting in favorable maternal and neonatal outcomes.